CD200 (Cluster of Differentiation 200), also known as OX-2 membrane glycoprotein, is a widely expressed membrane glycoprotein that belongs to the immunoglobulin superfamily. CD200 interacts with its receptor CD200R to deliver inhibitory signals that regulate the activation and function of immune cells, particularly myeloid cells including microglia in the brain, macrophages, and dendritic cells. This immune regulatory pathway has emerged as a critical mechanism in neurodegenerative diseases, where dysregulation of neuroinflammation plays a central role in disease progression.
CD200 is expressed on various cell types including neurons, astrocytes, and immune cells, while its receptor CD200R is primarily expressed on microglia and other myeloid cells. The CD200-CD200R interaction provides a crucial inhibitory signal that maintains microglia in a quiescent state under normal conditions. Loss of this signaling mechanism leads to microglial activation and chronic neuroinflammation, which is a hallmark of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
| Property |
Value |
| Gene Symbol |
CD200 |
| Protein |
OX-2 membrane glycoprotein |
| Synonyms |
OX2, OX-2, MOX1 |
| Chromosomal Location |
3q12-q13 (human) |
| NCBI Gene ID |
2051 |
| UniProt ID |
P41217 (human) |
| Gene Family |
Immunoglobulin superfamily |
| Protein Length |
278 amino acids |
| Molecular Weight |
~41 kDa |
The CD200-CD200R pathway provides critical inhibitory signaling:
CD200 (on neurons/astrocytes)
↓
Interaction with CD200R
↓
(on microglia/macrophages)
↓
ITIM recruitment
↓
Phosphatase activation (SHP-1, SHP-2)
↓
Signaling inhibition
↓
┌─────────────────┐
↓ ↓
↓炎症因子 ↓炎症因子
production production
↓ ↓
Microglial Macrophage
quiescence deactivation
- Immune regulation: Maintains immune cell quiescence
- Microglial control: Prevents excessive microglial activation
- Inflammation resolution: Promotes resolution of inflammation
- Tissue homeostasis: Maintains tissue immune homeostasis
- Self-tolerance: Contributes to immune tolerance
CD200 is widely expressed:
- Neurons: High expression in neurons throughout the brain
- Astrocytes: Expression on astrocytes
- Endothelial cells: Vascular expression
- Immune cells: Some expression on lymphocytes
- Other tissues: Lung, kidney, placenta
CD200 plays important roles in Alzheimer's disease pathogenesis:
- Microglial activation: Loss of CD200 leads to excessive microglial activation
- Pro-inflammatory cytokines: Increased IL-1β, TNF-α, IL-6
- Chronic inflammation: Sustained inflammatory state
- Aβ clearance: CD200 affects microglial phagocytic capacity
- CD200 restoration: Restoring CD200 may reduce neuroinflammation
- CD200R agonists: Agonistic antibodies being developed
- Neuroprotection: CD200 signaling provides neuroprotection
CD200 dysfunction contributes to Parkinson's disease:
- Dopaminergic neurons: CD200 expressed on dopaminergic neurons
- Neuroinflammation: Loss of CD200 enhances microglial activation
- Neuronal loss: Contributes to dopaminergic neuron death
- Alpha-synuclein: Interaction with protein aggregation pathology
- CD200 therapy: Gene therapy approaches to restore CD200
- CD200R activation: Agonist approaches
- Neuroprotection: Protection of dopaminergic neurons
- Motor neurons: CD200 expressed on motor neurons
- Microglial activation: Loss of CD200 in ALS models
- Disease progression: Contributes to disease progression
- Therapeutic target: CD200-based therapies being explored
- Striatal neurons: CD200 expression in striatum
- Neuroinflammation: Similar mechanisms to other disorders
- Therapeutic potential: CD200 modulation may be beneficial
- Demyelination: CD200 involved in demyelination processes
- Microglial control: Loss of inhibition
- Therapeutic approaches: CD200-based therapies in development
| Pathway |
Effect |
| SHP-1/2 |
Phosphatase recruitment |
| PI3K/Akt |
Pro-survival signaling |
| MAPK inhibition |
Reduces pro-inflammatory signaling |
| NF-κB inhibition |
Reduces cytokine production |
| Interactor |
Interaction Type |
Functional Effect |
| CD200R |
Receptor binding |
Inhibitory signaling |
| SHP-1 |
ITIM recruitment |
Phosphatase activation |
| SHP-2 |
ITIM recruitment |
Signaling inhibition |
| ITIMs |
Phosphotyrosine motifs |
Signal transduction |
- N-terminal IgV domain: Ligand binding
- IgSF domain: Immunoglobulin-like structure
- Transmembrane domain: Membrane anchoring
- Cytoplasmic tail: Short tail (minimal signaling)
| Approach |
Development Stage |
Description |
| CD200R agonists |
Preclinical |
Agonistic antibodies |
| CD200 gene therapy |
Preclinical |
Viral vector delivery |
| Peptide analogs |
Research |
CD200 mimetics |
| Small molecules |
Research |
Receptor modulators |
- CD200 agonists show efficacy in models
- Gene therapy approaches tested
- Combination with anti-inflammatory approaches
- No CD200-targeted therapies in clinical trials for neurodegeneration
- Immune checkpoint targeting in cancer (CD200 antagonist)
- Neuroinflammatory diseases as potential targets
- CRISPR-Cas9: CD200 knockout
- Recombinant proteins: CD200-Fc fusion
- Antibodies: Agonist and antagonist antibodies
- Fluorescent reporters: CD200 expression tracking
- CD200 knockout mice: Complete loss of CD200
- Transgenic models: Overexpression models
- Disease models: AD, PD, ALS models
- Flow cytometry: Cell surface expression
- Immunohistochemistry: Brain tissue analysis
- ELISA: Cytokine measurements
- Behavioral testing: Cognitive and motor function
- Human: Full-length CD200
- Mouse: Ortholog with high homology
- Rat: Similar structure and function
- Conserved: Essential immune regulatory function
CD200 represents an ancient immune regulatory system that has been conserved throughout evolution:
Phylogenetic Distribution:
- Mammals: Full CD200/CD200R signaling system
- Birds: Functional orthologs identified
- Fish: Simplified version present
- Invertebrates: Distant homologs in certain species
Functional Conservation:
- The Ig-like domain structure is conserved
- ITIM-based signaling is preserved
- Immune regulatory function maintained across species
CD200 expression is epigenetically regulated:
- Promoter methylation: Hypermethylation associated with reduced expression
- Tissue-specific patterns: Differential methylation across cell types
- Disease association: Altered methylation in neurodegenerative states
- Therapeutic potential: Demethylating agents affecting CD200
Histone marks influence CD200 expression:
- H3K27ac: Active enhancer marks in immune cells
- H3K4me3: Promoter activation
- HDAC involvement: Histone deacetylases regulate expression
MicroRNAs regulate CD200:
- miR-155: Targets CD200 in inflammatory states
- miR-124: Regulates microglial CD200R1
- Let-7 family: Expression modulation
CD200 participates in multiple protein interactions:
| Interactor |
Domain |
Binding Site |
Functional Consequence |
| CD200R1 |
Extracellular |
IgV domain |
Receptor binding, signal transduction |
| CD200R2 |
Extracellular |
IgV domain |
Alternative receptor |
| CD200R3 |
Extracellular |
IgV domain |
Decoy receptor |
| CD200R4 |
Extracellular |
IgV domain |
Species-specific |
| SHP-1 |
Cytoplasmic |
ITIM motif |
Phosphatase recruitment |
| SHP-2 |
Cytoplasmic |
ITIM motif |
Negative regulation |
| TRAF3 |
Cytoplasmic |
Unknown |
Signaling intermediate |
Crystal Structure Studies:
The extracellular domain of CD200 has been characterized:
- IgV domain: N-terminal immunoglobulin-like variable domain
- IgSF fold: Standard immunoglobulin superfamily topology
- Dimerization: Forms homodimers on cell surface
- Glycosylation: N-linked glycans affect function
Solution Structure:
- NMR studies reveal flexible regions
- Receptor binding induces conformational changes
- Dimer interface mapped
Small Molecule Agonists:
- Current status: Preclinical development
- Mechanism: Mimic CD200 binding to CD200R1
- Challenges: BBB penetration, selectivity
- Lead compounds: Various candidates in validation
Biologic Agents:
- CD200-Fc fusion proteins: Decoy receptors
- Agonist antibodies: Multiple candidates
- ADCs: Antibody-drug conjugates for targeted delivery
Currently, no clinical trials specifically targeting CD200 for neurodegenerative diseases are registered. However:
Related Trials:
- CD200/CD200R modulators in oncology (as immune checkpoint)
- Anti-inflammatory approaches in AD/PD
- Microglial modulation strategies
Expression Biomarkers:
- CD200 levels in CSF as neuroinflammation marker
- Soluble CD200 as disease biomarker
- Microglial CD200R1 as activation marker
Therapeutic Monitoring:
- Target engagement assays
- Pharmacodynamic markers
- Treatment response predictors
| Model |
Background |
Phenotype |
Reference |
| CD200 knockout |
C57BL/6 |
Spontaneous neuroinflammation |
Wright et al. |
| CD200 tg |
C57BL/6 |
Reduced microglial activation |
Konishi et al. |
| CD200 flox |
C57BL/6 |
Conditional deletion possible |
Mihrshahi et al. |
Alzheimer's Disease Models:
- APP/PS1 × CD200 KO: Accelerated pathology
- 5×FAD × CD200 KO: Enhanced inflammation
- CD200 overexpression: Protected phenotype
Parkinson's Disease Models:
- MPTP × CD200 KO: Exacerbated loss
- α-Syn × CD200 KO: Increased pathology
- CD200 overexpression: Neuroprotection
Testing paradigms for CD200 models:
- Cognitive testing: Morris water maze, Y-maze
- Motor testing: Rotarod, gait analysis
- Social behavior: Chamber tests
- Neuroinflammation markers: Iba1, CD68 quantification
CD200 intersects with multiple signaling networks:
CD200-CD200R1 Signaling Network
┌─────────────┐
│ NF-κB │
│ inhibition│
└──────┬──────┘
│
┌──────────┐ ┌────────▼────────┐
│ SHP-1 │──────▶│ Inflammatory │
│ SHP-2 │ │ Gene Suppression
└────┬─────┘ └────────▲────────┘
│ │
│ ┌────────┴────────┐
│ │ │
▼ ▼ ▼
┌─────────────────┐ ┌──────────┐ ┌─────────────┐
│ ITIM Signaling │ │Cytokine │ │ Phagocytosis│
│ │ │Reduction │ │ Modulation │
└─────────────────┘ └──────────┘ └─────────────┘
CD200 interacts with:
- Immune checkpoint proteins: PD-L1, CTLA-4 pathways
- Inflammasome components: NLRP3 regulation
- Toll-like receptor pathways: Cross-talk with TLR signaling
- Complement system: Regulation of complement-mediated inflammation
- Brain-penetrant agonists: Delivery to CNS
- Safe clinical candidates: Safety profile
- Biomarkers: Patient selection
- Combination therapy: With other approaches
- Gene therapy: AAV-mediated delivery
- Cell therapy: Stem cell approaches
- Biomarkers: Inflammatory markers
- Personalized medicine: Genetic markers
- Structural studies: Full CD200/CD200R complex
- Functional validation: Human-relevant models
- Clinical translation: Safe and effective therapeutics
- Biomarker development: Patient stratification